The main purpose of this legislation is to classify tianeptine as a controlled substance under the Controlled Substances Act. This is intended to address concerns about the potential misuse and abuse of tianeptine, which has been linked to harmful effects similar to those of opioids. Key provisions of the legislation include the formal scheduling of tianeptine as a Schedule III substance. This means that tianeptine, along with its various forms and derivatives, will be regulated more strictly.